SynAct Pharma AB (“SynAct”) today announced that a European patent was granted covering the company’s leading drug candidate AP1189 in methods of treating kidney diseases.
SynAct has received information that its European patent EP 3 743 064 B1 was granted on 11 August 2021. The European patent provides exclusivity on the medical use of AP1189 and similar compounds in treating kidney disease, specifically primary nephrotic syndrome, and including membranous nephropathy which is currently being tested in clinical trials.
The European patent will now be validated in selected European contracting states.
This follows on to the information conveyed in the press release by SynAct on 13 April 2021 informing on the ‘Intention to grant” of a European patent; this European patent has now finally proceeded to grant, as expected.
“Granting of the patent is fortifying a strong and robust patent portfolio for our lead drug candidate AP1189. SynAct Pharma intends to further develop AP1189 for different indications with great unmet medical need, including some of which are covered by the new patent,” said SynAct’s CSO Thomas Jonassen.
The information was submitted, through the agency of the contact person below, for publication on August 25, 2021
For further information about SynAct Pharma AB, please contact:
Jeppe Øvlesen Thomas Jonassen
CEO, SynAct Pharma AB CSO, SynAct Pharma AB
Phone: +45 28 44 75 67 Phone: +45 40 15 66 69
Mail: [email protected] Mail: [email protected]